Get Started
Companies › ARDX

Ardelyx

ARDX · NASDAQ
Commercial StageSmall MoleculeGi Nephrology

Ardelyx is a commercial-stage biopharmaceutical company focused on developing and commercializing medicines for gastrointestinal and cardiorenal diseases. The company's two approved products — IBSRELA (tenapanor) for IBS-C and XPHOZAH (tenapanor) for hyperphosphatemia in CKD on dialysis — are both based on the same NHE3 inhibitor platform. Both products are experiencing rapid commercial uptake.

Market Cap
$1.7B
Cash Runway
—
Pipeline
3 Assets
Priority
Medium
Investment Thesis

Bull Case

  • Revenue acceleration — both products growing >70% YoY; IBSRELA Q3 $78.2M (+92% YoY)
  • Only non-secretagogue in IBS-C — 77% of patients on secretagogues still symptomatic
  • XPHOZAH addresses massive unmet need — 50% of dialysis patients have uncontrolled phosphorus

Bear Case

  • Patent cliff in August 2033 limits peak value capture; RDX10531 next-gen in development
  • Single molecule risk — both products are tenapanor; any safety signal affects both

Pipeline

Asset Target Stage Lead Indication Next Catalyst
IBSRELA NHE3 Approved Irritable Bowel Syndrome with Constipation (IBS-C) FY2025 revenue report (Q1 2026)
RDX10531 NHE3 IND-enabling Multi-therapeutic NHE3 franchise extension IND submission for RDX10531 (2026)
XPHOZAH NHE3 Approved Hyperphosphatemia in CKD patients on dialysis FY2025 XPHOZAH revenue report (Q1 2026)
Data sourced exclusively from public filings, corporate presentations, and published clinical data. For informational purposes only. Not investment advice. Satya Bio does not provide recommendations to buy or sell securities. Terms · Privacy